Impact of monocyte–macrophage inhibition by ibandronate on graft function and survival after kidney transplantation: a single-centre follow-up study over 15 years

  • Frank-Peter Tillmann
  • Wolfgang Grotz
  • Lars Christian Rump
  • Przemyslaw Pisarski
Original article

Abstract

Background

The aim of this study was to evaluate the effect of ibandronate administration on long-term graft function and graft survival after successful renal transplantation.

Methods

Seventy-two renal transplant recipients (36 patients each in the treatment and control group) were included and followed over a 15-year period. Data on graft function and death-censored transplant outcome were recorded at 1, 5, 10, and 15 years.

Results

Death-censored Kaplan–Meier analysis showed significantly improved graft survival of the treatment group (p = 0.026), whereas Cox regression analysis showed that ibandronate was positively associated with improved transplant survival (p = 0.028, hazard ratio 0.24, 95% confidence interval 0.07–0.86). Although general linear modelling did not indicate that ibandronate had a significant effect on transplant function (calculated using the estimated glomerular filtration rate according to Chronic Kidney Disease Epidemiology Collaboration equation) over the entire 15-year period (p = 0.650), there was a tendency towards improved graft function 1-year post-transplantion (p = 0.056).

Conclusions

Ibandronate treatment within the first year of transplantation resulted in a trend towards better graft function within the first few year post-transplant, and was associated with increased transplant survival at long-term follow-up.

Keywords

Ibandronate Bisphosphonate Renal transplantation Long-term follow-up Macrophages Monocytes 

References

  1. 1.
    Hancock WW, Thomson NM, Atkins RC. Composition of interstitial cellular infiltrate identified by monoclonal antibodies in renal biopsies of rejecting human renal allografts. Transplantation. 1983;35:458–63.CrossRefPubMedGoogle Scholar
  2. 2.
    Sansoni P, Passeri G, Fagnoni F, Mohagheghpour N, Snelli G, Brianti V, Engleman EG. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res. 1995;10:1719–25.CrossRefPubMedGoogle Scholar
  3. 3.
    Van der Veen G, Broersma L, Dijkstra CD, van Rooijen N, Van Ri G, van der Gaag R. Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest Ophthalmol Vis Sci. 1994;35:3505–15.PubMedGoogle Scholar
  4. 4.
    Fryer J, Grant D, Jiang J, Metrakos P, Ozcay N, Garcia B, Behme R. Influence of macrophage depletion on bacteria translocation and rejection in small bowel transplantation. Transplantation. 1996;62:553–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Fox A, Koulmanda M, Mandel TE, van Rooijen N, Harrison LC. Evidence that macrophages are required for T-cell infiltration and rejection of fetal pig pancreas xenografts in nonobese diabetic mice. Transplantation. 1998;66:1407–16.CrossRefPubMedGoogle Scholar
  6. 6.
    Wu G, Korsgren O, van Rooijen N, Wennberg L, Tibell A. The effect of macrophage depletion on delayed xenograft rejection: studies in the guinea pig-to-C6-deficient rat heart transplantation model. Xenotransplantation. 1999;6:262–70.CrossRefPubMedGoogle Scholar
  7. 7.
    Chadban SJ, Wu H, Hughes J. Macrophages and kidney transplantation. Semin Nephrol. 2010;30:279–89.CrossRefGoogle Scholar
  8. 8.
    Toki D, Zhang W, Hor KL, Liuwantara D, Alexander SI, Yi Z, Sharma R, Chapman JR, Nankivell BJ, Murphy B, O’Connell PJ. The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation. Am J Transpl. 2014;14:2126–36.CrossRefGoogle Scholar
  9. 9.
    Hutchinson JA. Macrophages in transplantation. Transplantation. 2015;99:898–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12:1530–7.PubMedGoogle Scholar
  11. 11.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Loupy A, Vernerey D, Tinel C, Aubert O, van Huyen JPD, Rabant M, Verine J, Nochy D, Empana JP, Martinez F, Glotz D, Jouven X, Legendre C, Lefacheur C. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol. 2015;26:1721–31.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and application. J Immunol Methods. 1994;174:83–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Garcia MR, Ledgerwood L, Yang Y, Xu J, Lal G, Burrell B, Ma G, Hashimoto D, Li Y, Boros P, Grisotto M, van Rooijen N, Matesanz R, Tacke F, Ginhoux F, Ding Y, Chen AH, Randolph G, Merad M, Bromberg JS, Ochando JC. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest. 2010;120:2486–96.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Halloran PF, Chang J, Famulski K, Hidalgo LG, Salazar IDR, Merino Lopez M, Matas A, Picton M, de Freitas D, Bromberg J, Seron D, Sellarés J, Einecke G, Reeve J. Disappearance of T-cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol. 2015;26:1711–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transpl. 2012;12:1157–67.CrossRefGoogle Scholar
  17. 17.
    Moreso F, Carrera M, Goma M, Hueso M, Sellares J, Martorell J, Grinyó JM, Serón D. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation. 2012;93:41–6.CrossRefPubMedGoogle Scholar
  18. 18.
    El Ters M, Grande JP, Keddis MT, Rodrigo E, Chopra B, Dean PG, Stegall MD, Cosio FG. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transpl. 2013;13:2334–41.CrossRefGoogle Scholar
  19. 19.
    Schaub S, Nickerson P, Rush D, Mayr M, Hess C, Golian M, Stefura W, Hayglass K. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transpl. 2009;9:1347–53.CrossRefGoogle Scholar
  20. 20.
    Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, Goebel J, Gibson IW, Fairchild RL, Riggs M, Spain K, Ikle D, Bridges ND, Heeger PS. CTOT-01 consortium. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transpl. 2013;13:2634–44.CrossRefGoogle Scholar
  21. 21.
    Bergler T, Jung B, Bourier F, Kühne L, Banas MC, Rümmele P, Wurm S, Banas B. Infiltration of macrophages correlates with severity of allograft rejection and outcome in human kidney transplantation. PLoS One. 2016;11:e0156900.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Michëlsson K, Aspenberg M. Postmenopausal osteoporosis. N Engl J Med. 2016;374:2095.CrossRefGoogle Scholar
  23. 23.
    Ott SM. Postmenopausal osteoporosis. N Engl J Med. 2016;374:2095–6.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2017

Authors and Affiliations

  • Frank-Peter Tillmann
    • 1
  • Wolfgang Grotz
    • 2
  • Lars Christian Rump
    • 1
  • Przemyslaw Pisarski
    • 3
  1. 1.Klinik für Nephrologie, Heinrich Heine Universität DüsseldorfDüsseldorfGermany
  2. 2.Klinik für Innere Medizin II, Alfried Krupp Krankenhaus RüttenscheidEssenGermany
  3. 3.Department Chirurgie, Klinik für Allgemein-und Viszeralchirurgie, TransplantationszentrumUniversitätsklinikum FreiburgFreiburgGermany

Personalised recommendations